• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of plosgenPLoS GeneticsSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)View this Article
PLoS Genet. Apr 2006; 2(4): e51.
Published online Apr 7, 2006. Prepublished online Feb 23, 2006. doi:  10.1371/journal.pgen.0020051
PMCID: PMC1428788

Genome-Wide Analysis of Menin Binding Provides Insights into MEN1 Tumorigenesis

Michael Snyder, Editor

Abstract

Multiple endocrine neoplasia type I (MEN1) is a familial cancer syndrome characterized primarily by tumors of multiple endocrine glands. The gene for MEN1 encodes a ubiquitously expressed tumor suppressor protein called menin. Menin was recently shown to interact with several components of a trithorax family histone methyltransferase complex including ASH2, Rbbp5, WDR5, and the leukemia proto-oncoprotein MLL. To elucidate menin's role as a tumor suppressor and gain insights into the endocrine-specific tumor phenotype in MEN1, we mapped the genomic binding sites of menin, MLL1, and Rbbp5, to approximately 20,000 promoters in HeLa S3, HepG2, and pancreatic islet cells using the strategy of chromatin-immunoprecipitation coupled with microarray analysis. We found that menin, MLL1, and Rbbp5 localize to the promoters of thousands of human genes but do not always bind together. These data suggest that menin functions as a general regulator of transcription. We also found that factor occupancy generally correlates with high gene expression but that the loss of menin does not result in significant changes in most transcript levels. One exception is the developmentally programmed transcription factor, HLXB9, which is overexpressed in islets in the absence of menin. Our findings expand the realm of menin-targeted genes several hundred-fold beyond that previously described and provide potential insights to the endocrine tumor bias observed in MEN1 patients.

Synopsis

In multiple endocrine neoplasia type I, absence of the nuclear factor menin gives rise to endocrine tumors by a mechanism that is poorly understood. Using state-of-the-art genome-wide chromatin-immunoprecipitation coupled with microarray analysis technology, this paper significantly enlarges our understanding of the role of menin by greatly extending the number of gene targets where menin binds. The authors show that while menin frequently colocalizes with a protein complex that modifies chromatin structure, menin can also bind to many other promoters by an alternative mechanism. They also present data that potentially implicate one of the menin target genes, HLXB9, in the endocrine specificity of tumorigenesis in multiple endocrine neoplasia, type 1. Further experiments to confirm the role of HLXB9 in tumorigenesis are necessary and may help explain how the loss of a ubiquitously expressed tumor suppressor gene can give rise to tumors in specific tissues.

Introduction

The hallmark of multiple endocrine neoplasia type I (MEN1), is the development of tumors in the parathyroid, anterior pituitary, and enteropancreatic endocrine cells. Other associations occasionally found in MEN1 patients include foregut carcinoids, facial angiofibromas, lipomas, collagenomas, meningiomas, and smooth muscle tumors. MEN1 patients typically inherit loss of function mutations in the MEN1 gene, and tumors arise following loss of the remaining wild-type allele. Thus, the MEN1 gene follows the classic “two-hit” tumor suppressor model first proposed by Knudson for retinoblastoma [1]. Somatic mutations in the MEN1 gene are also frequently found in sporadic parathyroid adenomas, insulinomas, gastrinomas, and lung carcinoids [26], indicating that loss of the MEN1 gene is a major contributor to the development and maintenance of many nonhereditary endocrine tumors. There is currently no prevention of or cure for MEN1 cancers, and cancer treatment options are generally limited to surgical interventions.

The protein product of MEN1, menin, is a ubiquitously expressed 67-kDa protein found predominantly in the nucleus [7]. Studies in Men1 knockout mice support menin's role as a tumor suppressor [8,9]. Mice that are homozygous null for Men1 show developmental defects and die at embryonic day 11.5 to 13.5. Heterozygous Men1 mice eventually develop multiple endocrine tumors that arise following somatic loss of the wild-type Men1 allele, and the spectrum of tumors observed in Men1+/ mice is remarkably similar to that in human MEN1 kindreds. We and others have also successfully developed conditional knockouts of the Men1 gene, using the Cre-lox system [1012]. When homozygous Men1 “floxed” mice are bred to animals expressing Cre recombinase in the beta cells of the pancreatic islets, the resultant progeny develop multiple pancreatic insulinomas. These insulinomas arise long after homozygous inactivation of the Men1 gene, suggesting that additional somatic events are required for frank tumor formation. Men1−/− insulinomas are capable of developing in the absence of chromosomal or microsatellite instability, suggesting that the additional somatic events required for tumor formation are subtle, occurring at either the nucleotide or epigenetic level [13].

Although inherited mutations in the MEN1 gene predispose individuals to several types of tumors, there is a particularly striking predisposition to tumors in endocrine tissues. The development of tumors in this endocrine-specific pattern is quite puzzling as menin appears to be expressed in all tissues. In a previous study, we set out to gain insights to this issue of tissue-specificity in MEN1 by breeding floxed Men1 mice to transgenic mice expressing Cre recombinase from the albumin promoter, which is predominantly expressed in liver hepatocytes [14]. This strategy allowed us to assess the loss of menin in liver, a tissue not normally predisposed to developing tumors in humans or mice with heterozygous MEN1 loss of function mutations. Progeny that were homozygous for a floxed Men1 allele and expressing Cre showed a nearly complete loss of Men1 mRNA and corresponding protein levels in the liver, yet the overwhelming majority of menin-null livers were histologically normal and remained tumor free. These findings suggest that in liver, menin's tumor suppressor function or functions are dispensable.

Menin has been reported to interact with a multitude of proteins including JunD, SMAD family members, Pem, NFκB, FANCD2, RPA2, NMMHC II-A, GFAP, vimentin, and Hsp70 [15]. The diverse functions of the menin partners suggest roles for menin in transcriptional regulation, DNA processing and repair, cytoskeletal organization, and protein degradation, although to date none of the interacting partners have been directly proved important in MEN1 pathophysiology. No convincing evidence of direct binding of menin to DNA has been shown, but menin has been shown to associate with a multimember protein complex whose composition is highly similar to that of the SET1 histone methyltransferase complex of yeast and humans [16,17]. Members of this complex include HCF-2 (host cell factor 2), Rbbp5 (retinoblastoma binding protein 5), WDR5 (WD repeat domain 5), and trithorax proteins MLL1/MLL2 (mixed-lineage leukemia) and ASH2 (absent, small, or homeotic). The menin-HMT–associated complexes promote methylation of histone H3 tails at lysine 4 (H3 K4), an epigenetic mark that is generally associated with active gene transcription. At the time of this study, five target genes positively regulated by menin and MLL have been reported in various tissues [1619]. These targets include the clustered homeobox genes, HOXA9, c6, and c8, and two cyclin-dependent kinase (CDK) inhibitors involved in cell cycle regulation, p27Kip1 and p18Ink4c.

It has been hypothesized that menin mediates its tumor suppressor action by regulating histone methylation in promoters of HOX genes and/or p18, p27, and possibly other CDK inhibitors [18,19]. Consistent with this hypothesis, H3 K4 methylation and expression of p18 and p27 were shown to be dependent on menin in pancreatic islets [18]. An additional clue for a role for p18 and p27 in MEN1 pathophysiology comes from studies in knockout mice [20]. The simultaneous loss of p18 and p27 in mice leads to a tumor spectrum that is similar to that in human MEN1 and MEN2 patients, including tumors in the pituitary, parathyroid, thyroid, endocrine pancreas, stomach, and duodenum. These findings raise critical questions regarding the function of menin and the basis of endocrine-tumor formation in MEN1. (1) Does menin mediate its tumor suppressor action by governing the expression of HOX and cell cycle genes alone or through additional key targets that have not yet been identified? (2) Does menin only target genes whose transcription is trithorax dependent, or can menin also target genes independently of MLL and its associated HMT complex members? (3) Could the specific bias for endocrine tumor formation in MEN1 result from differences in distinct genes that are targeted by menin in the endocrine tissues?

To gain a more complete understanding of the action of menin tumor suppression, we identified the genomic occupancy of menin and two associated HMT complex members, MLL1 and Rbbp5, using chromatin immunoprecipitation coupled with DNA microarray analyses (ChIP-chip) [21]. Given the evidence that the menin-HMT complex methylates histone H3 at lysine 4 [16,18], we also mapped the positions of H3 K4 (trimethylation) by ChIP-chip. Our data in HeLa S3, HepG2, and human pancreatic islet cells indicate that menin occupies the promoter regions of thousands of human genes, suggesting that menin acts as a global regulator of transcription. Menin occupancy frequently coincides with MLL1, Rbbp5, and H3 K4, but menin can also target promoters independently of the HMT complex. Factor occupancy generally correlates with high gene expression, and loss of menin in pancreatic islets, by and large, does not affect transcript levels. Last, we present a model for tumor suppression by MEN1 and offer insights into the endocrine tumor bias observed in MEN1 patients.

Results

Pattern of Menin Binding at HOX Clusters and Elsewhere

We set out to investigate the genomic occupancy of menin using ChIP-chip. Recent evidence suggesting that menin associates with an SET1-like HMT complex to regulate HOX gene expression [16,17] prompted us to design a microarray containing oligonucleotides tiled at high density across the HOX A, B, C, and D loci. To determine if menin preferentially binds to genes that contain homeobox domains, our arrays also included oligonucleotides corresponding to more than 100 homeodomain-containing genes located outside of the four HOX clusters. We also tiled probes corresponding to approximately 20 megabases (Mb) of random sequence on Chromosome 7, to assess menin occupancy in regions located at large distances from genes. As a pilot effort, we hybridized these HOX-centered microarrays with menin-chromatin immunoprecipitated DNA from HeLa S3 cells. A computer program incorporating a sliding window and threshold approach, ACME (Algorithm for Capturing Microarray Enrichment), was used to identify genomic sites enriched for menin-binding (Figure 1).

Figure 1
Strategy Used to Analyze Data from Tiled Microarrays

Hybridizations to these HOX arrays with menin-chromatin immunoprecipitated DNA from HeLa S3 cells revealed striking differences between menin occupancy at the clustered HOX genes as compared to elsewhere. For genes located outside the four HOX clusters, menin was frequently localized to 5′ promoter regions, at or very near transcriptional start sites (Figure 2A and and2B).2B). Little to no signal was detected in intragenic regions, or at 3′ untranslated regions. Menin occupancy at the HOX clusters was more extensive, with broad footprints that spanned intergenic and intragenic portions of HOX genes (Figure 2C). Specifically, within the HOX A cluster, menin sites clustered at HOXA6, A10, A11, and A13. Extensive binding to the HOX C cluster was also detected, with broad signals that extended across HOXC11, C10, C9, and portions of C4 and C6. Menin sites were also detected near HOXB6 and HOXB7, but the pattern of binding was less extensive than that detected at the HOX A and C loci. No significant menin binding was detected at the HOX D locus. Menin sites were also detected at several other homeobox genes located outside the four HOX clusters, but similar to other non-HOX loci, binding was localized to 5′ promoter regions (unpublished data). Our finding that menin binds to HOXA9, C6, and C8 is consistent with prior studies in which these three HOX genes were identified by standard ChIP-PCR [16,17] and supports the reliability of the ChIP-chip methodology used here for detecting genomic binding events by menin.

Figure 2
General Pattern of Menin Occupancy in HeLa S3 Cells

Genome-Wide Distribution of Menin in Multiple Cell Types

The results of the pilot study above indicate that, except for the HOX clusters, menin occupancy is highly specific for 5′ regions of genes. Based on these findings, we rationalized that menin sites could be identified on a near genome-wide scale by interrogating only those regions of DNA that correspond to the 5′ portions of genes. We therefore designed a second DNA microarray containing tiling oligonucleotides across the 5′ regions of approximately 20,000 human genes. Given the binding pattern of menin at the HOX clusters, this array also contained tiled oligos across all four clustered HOX loci, as well as the complete sequence of 381 genes (−5,000 bp relative to the transcription start site to +5,000 bp relative to the transcription stop site) that showed evidence of menin occupancy on previous arrays (PCS, unpublished data). These promoter arrays were hybridized with menin-chromatin immunoprecipitated DNA from human islets, HeLa S3 and HepG2 cells. To assess if the bias for endocrine-tumor formation in MEN1 might be related to differences in distinct target genes in endocrine cells, we compared sites occupied in HeLa S3 and HepG2 cells to those identified in human pancreatic islet cells. As expected, hybridizations with menin-chromatin immunoprecipitated DNA from HeLa S3 cells revealed broad signals at the HOX clusters and promoter-specific signals at most other loci (Figure 3A and and3B).3B). In HepG2 and pancreatic islet cells, the vast majority of menin sites were also detected in promoter regions, at or near transcriptional start sites. Notable differences in the pattern of menin binding were detected at the HOX clusters. Whereas multiple menin sites were detected at the HOX A and C clusters in HeLa cells, relatively little signal was detected at these clusters in HepG2 cells and pancreatic islets (Figure 3A and unpublished data). By using a stringent selection criterion of p < 0.0001, we found that menin occupies 1,706 sites in HeLa S3 cells, 2,239 sites in HepG2 cells, and 1,541 sites in pancreatic islet cells. Sites that were concordant and discordant between each cell type are depicted in a Venn diagram (Figure 3C). The finding that menin binds to a broad range of human promoters in all three cell types suggests that menin has a global role in transcription in both endocrine and non–endocrine-derived cells.

Figure 3
Occupancy of Menin, MLL, Rbbp5 Frequently Overlaps with Trimethylation of Lys4 at Histone H3

Overlap of Genomic Occupancy of Menin, MLL, Rbbp5, and the H3 K4 Trimethyl Mark

Based on published evidence that menin associates with a HMT complex containing MLL, Ash2L, WDR5, and Rbbp5, we set out to determine if the genomic occupancy of menin coincides with two other members of this complex, MLL1 and Rbbp5. Given the ability of the SET1/MLL complex to catalyze the trimethlyation of histone H3 at lysine 4, we also mapped the genomic distribution of the H3 K4 trimethyl mark. Results for the HOX A cluster are shown in Figure 3A, where the binding patterns for menin, MLL1, Rbbp5, and H3 K4 are seen to be similar, although menin shows a more contiguous binding pattern across HOXA9, A10, A11, and A13. For non-HOX promoters, different binding combinations were seen for different promoters; for illustration, Figure 3B displays a promoter where all factors bind near the transcriptional start site, but that was not always the case.

It is not uncommon for ChIP-chip data to reveal dramatic differences in the intensity of hybridization signals at multiple loci [22]. While some loci appear highly enriched, others appear modestly enriched, and other loci entirely lack signal. Differences in signal intensities could reflect true differences in occupancy of the factor or could represent slight differences in amplification or hybridization of chromatin immunoprecipitated DNA. Because of the broad dynamic range in signal, assessing the overlap between different factors at multiple loci at a given significance threshold locus can be challenging (Figure 4A). To depict the overlap more accurately between sites occupied by each factor, we selected promoters that were occupied by menin and MLL1 at high confidence (p < 0.0001), and then plotted the corresponding p-values for each associated factor as a heatmap. Heatmaps from all three cell types indicate that a large proportion of promoters are bound by all factors (Figure 4B and and4C).4C). The data also reveal distinct sets of promoters occupied by menin and not MLL1 or Rbbp5, and vice versa. Setting stringent cutoffs for bound (p < 0.0001) and unbound (p > 0.1), the percentage of menin sites that were also bound by MLL1 and Rbbp5 were as follows: 49.3% in HeLa S3 cells; 56.7% in HepG2 cells, and 46.1% in pancreatic islets. The percentage of menin sites that did not coincide with both MLL1 and Rbbp5 was lower: 21.7% in HeLa cells, 9.5% in HepG2 cells, and 2.4% in pancreatic islets. These results suggest that menin targets promoters in cooperation with HMT complex members MLL1 and Rbbp5, but that menin can also occupy promoters in cooperation with other unidentified factors that may not be part of the HMT complex.

Figure 4
Menin Sites Can Be Bound in the Presence or Absence of HMT Complex Members

Validation of Factor Binding by Real-Time PCR

We used a standard approach that combines conventional ChIP and real-time PCR to assess the reliability of the ChIP-chip method and our approach for analysis of the raw microarray data (Figures 4D and and5).5). We arbitrarily selected 67 promoter regions that were identified by our windowing and threshold analyses to be enriched for menin binding at p < 0.0001. These sites were compared to 15 random promoter regions (0.001 < p < 1) and seven random regions of the genome located outside of promoter regions. On average, promoters that had a p-value of <0.0001 were enriched 7.25-fold over random regions (Figure 5A). Furthermore, of the 67 sites that were shown to be enriched by ChIP-chip (p < 0.0001), 64 (95.5%) were confirmed by real-time PCR to have enrichment ratios that were greater than those detected for the randomly selected amplified regions. These data indicate that sites we determined to be enriched at p < 0.0001 by ChIP-chip reliably detect enriched sites of menin binding. Many factor-bound sites probably also exist within the p = 0.01 to 0.001 confidence interval, but negative control studies suggest that false-positive rates increase as p-values rise above 0.0001 (Figure 5C). Relative enrichment using antibodies to H3 K4 was also tested (Figure 5B). Consistent with the tight physical association between DNA and histones, enrichment of H3 K4–bound sites was greater than that for menin sites.

Figure 5
Enrichment of Selected Genomic Regions

Comparison of ChIP-Chip and Gene Expression

The ChIP-chip data in all three cell types indicate that menin occupancy frequently coincides with trimethylation of histone H3 at lysine 4, a mark that is generally associated with a transcriptionally active state of chromatin. These results prompted us to assess whether factor occupancy correlates with high levels of gene expression. A systematic comparison between ChIP-chip and expression data in all three cell types revealed that genes whose promoters are bound by menin correlate with higher mRNA expression levels (Figure 6A and unpublished data). This was true for gene subsets both where menin bound concordantly with MLL and Rbbp5 and where menin bound without these factors. These data suggest that menin, in both the presence and absence of the HMT complex, is generally associated with transcriptionally active promoters.

Figure 6
Factor Occupancy Correlates with High Gene Expression but Absence of Menin Does Not Generally Affect Gene Expression Levels

Comparison of ChIP-Chip and Expression Data from Mice That Are Conditionally Null for Men1

The ChIP-chip and expression data indicate that menin targets a broad range of promoters that are generally transcriptionally active. Given these findings, one might predict that menin may function to maintain steady-state gene expression and that loss of menin might lead to reduced expression of genes normally targeted by menin and the HMT complex. To test whether menin-targeted genes show alterations in expression in cells that lack menin, we determined in vivo expression changes incurred upon menin loss in a mouse model of MEN1. Specifically, we compared human ChIP-chip data to expression data from islets isolated from wild-type mice or from mice that were conditionally null for Men1 in the beta cells (genotype: RIP-cre; Men1loxP/loxP). Islets from these mice develop tumors long after (30 to 50 wk) homozygous inactivation of the Men1 alleles and thus provide the opportunity to detect expression changes more closely related to menin loss than at later stages of neoplastic transformation, when secondary activating or inactivating mutations have accumulated. Microarray analyses were performed using RNA from highly purified pancreatic islets isolated from 15- and 25-wk mice that were conditionally null for Men1. Controls included islets from age- and sex-matched wild-type and RIP-cre transgenic animals. At 15 wk, Men1/ islets appear relatively normal in size and morphology. By 25 wk, the majority of Men1/ pancreatic islets appear hyperplastic and occasionally contain small adenomatous lesions [12].

Similar to the results of previous comparisons between ChIP-chip and gene expression data, genes whose promoters were bound by menin (p < 0.0001) correlated with high expression in wild-type mouse islets (Figure 6B). Contrary to what one might predict given the broad range of promoters targeted by menin, we did not detect significant differences in the expression of menin-targeted genes in 15- and 25-wk menin-null islets compared to wild-type (Figure 6B). Since overall expression levels remained generally unchanged in the null state, we turned our attention to the exceptions. One hundred eighty-four individual genes whose promoters were bound by menin in wild-type human islets showed alterations in expression in Men1 null mouse islets at the 15-wk time point (Figure S1). Of these 184 genes, 110 were upregulated in the absence of menin and 74 were downregulated. Consistent with the prior evidence suggesting that menin positively regulates p18 in islets [18], p18 (CDKN2C) was found to be significantly reduced in expression in Men1/ islets.

Analysis of Hlxb9

Given the specific bias for endocrine tumor formation in MEN1, we focused on genes that were bound by menin in islets and not in HeLa S3 or HepG2 cells, and whose expression was altered in menin-null islets. Twenty-four such genes were found; 12 of these were upregulated in menin-null islets compared to wild-type islets and 12 were downregulated. Of these 24 genes, only seven were significantly different at both the 15- and 25-wk time points. One of these candidates was the transcription factor Hlxb9. HLXB9 encodes HB9, a homeodomain protein predominantly expressed in adult pancreas and developing motor neurons [23,24]. Of particular interest, HLXB9 is key to normal pancreas development and function, and mice that are homozygous null for Hlxb9 fail to develop the dorsal lobe of the pancreas [25,26]. The remnant Hlxb9/- pancreas has small islet cells, with reduced numbers of insulin-producing beta cells. Early overexpression of Hlxb9 in pancreatic epithelium results in a complete disruption of pancreatic development [27]. In humans, dominantly inherited loss of function mutations in HLXB9 causes Currarino syndrome, a developmental disorder characterized by partial sacral agenesis, a presacral mass, and anorectal and urogenital malformations [2830]. Activation of HLXB9 expression may be induced by chromosomal rearrangements in acute lymphoblastic leukemia [31,32].

To test the possibility that menin regulates beta cell–specific expression of Hlxb9 and to validate the microarray results described above, we measured gene expression by RT-PCR in Men1/ pancreatic islets and islet tumors isolated from a cohort of conditionally null Men1 mice (Figure 7). Compared to islets isolated from wild-type mice, expression of Hlxb9 was significantly increased in 15- and 25-wk Men1/ islets. Consistent with these findings, immunohistochemical analyses in a conventional Men1 knockout animal revealed increased Hb9 expression in atypical hyperplastic islets and tumor tissue. Collectively, these findings suggest activation of Hlxb9 in response to menin loss might contribute to islet beta cell tumorigenesis.

Figure 7
Hb9 Expression Is Elevated in Islets from Conventional and Conditional Men1 Knockout Mice

Menin Occupancy at p18 and p27 Loci

Recent reports suggesting that menin can positively regulate p18 and p27 [18] prompted us to investigate ChIP-chip and expression data at these two loci. We detected intense ChIP hybridization signals for menin, MLL, and H3 K4 trimethylation at the promoters of both p18 and p27 in HeLa S3, HepG2, and pancreatic islet cells. Menin, MLL, and H3 K4 occupancy at p18 and p27 loci also coincided with Rbbp5 binding in HeLa and HepG2 cells but not in pancreatic islets. Consistent with previous findings [18], we detected reduced expression of p18 in Men1/ islets by microarray analyses (Figure S1), and this was validated by real-time RT-PCR (unpublished data). Alterations in p27 expression levels were not detected in null islets.

Given that menin was found by ChIP-chip to occupy p18 and p27 in all three cell types, we next set out to determine if the absence of menin affects p18 and p27 expression levels in a nonendocrine tissue. In an effort to gain insights into tissue specificity in MEN1, we previously used the Cre-lox system to generate mice that are homozygous null for Men1 in liver [14]. Mice with Men1/ livers showed a nearly complete loss of Men1 mRNA corresponding protein levels, yet the menin-null livers remain tumor free. To assess if menin maintains p18 and p27 expression in liver, we measured p18 and p27 gene expression by RT-PCR in liver tissues isolated from these mice. Compared to wild-type control livers, the expression of p18 and p27 in Men1-null livers was reduced 89% and 63%, respectively (unpublished data). Collectively, these data support the conclusion that menin enhances expression of p18 and p27 in both pancreatic islets and liver. Since the absence of menin gives rise to tumors only in endocrine pancreas, not in liver, mechanisms beyond simple dysregulation of p18 and p27 must be involved.

Discussion

We set out to investigate menin's role as a transcriptional regulator by identifying genes bound by and dependent on menin. Prior to this study, the only genes reported to be targeted by menin and MLL were Hoxc6, Hoxc8, HOXA9, p27, and p18. Our findings indicate that menin does not only target specific classes of genes like HOX and CDK inhibitors but that menin also targets a very broad range of promoters in multiple tissues. This expands the realm of menin-targeted genes several hundred-fold. We find that menin occupancy frequently coincides with members of the HMT complex, MLL1 and Rbbp5, as well as the H3 K4 trimethyl mark, raising the possibility that menin functions as a general transcriptional regulator that helps maintain stable gene expression. Averaged over thousands of genes, menin correlates with higher gene expression, but overall expression levels do not decrease upon loss of menin in null islets. Surprisingly, menin binds many regions of the genome independently of the HMT complex members, suggesting that menin may regulate transcription by cooperating with other, currently unknown proteins. Possible candidates include JunD, SMADs, NFκB, or other menin-associated transcription factors not part of the SET1/MLL complex.

A fundamental question for many tumor suppressor syndromes is the tissue specificity of tumor formation. Menin is expressed in nearly all tissues. Why do MEN1-associated tumors arise primarily in endocrine organs? Could the interactions between menin, MLL, and HOX gene expression suggest an explanation for the endocrine specificity?

MLL is an important regulator of HOX gene expression, and leukemic chromosomal translocations involving MLL appear to act by creating chimeric fusion proteins that constitutively activate HOX genes [3335]. The persistent expression of HOX genes results in a failure of terminal differentiation, and studies in mice have shown that overexpression of certain HOX genes, Hoxa9 and Meis1 in particular, leads to leukemogenesis [36,37]. Previous studies have also shown that menin can positively regulate HOXA9 in HeLa cells and Hoxc6 and Hoxc8 in developing mouse embryo [16,17]. Collectively, these findings have led to the enticing hypothesis that tumorigenesis in MEN1, like leukemogenesis, is related to dysregulation of HOX genes normally bound by menin and MLL. If this hypothesis is valid, however, we would have expected to see menin occupancy at the HOX clusters in pancreatic islets. While we did detect extensive binding of menin (and MLL) to the HOX A and C clusters in HeLa S3 cells, virtually no signal was detected in either HepG2 cells or pancreatic islets. Moreover, the clustered homeobox genes are expressed at almost undetectable levels in pancreatic islets, and none of them significantly change in expression following loss of menin. Given these findings and the contrasts of menin function in myeloid versus endocrine tumors, we believe it is unlikely that dysregulation of HOX genes in islet cells contributes to MEN1 islet neoplasms.

If HOX genes are not the mediator, then how does menin loss lead to endocrine tumors? Menin was recently proposed to regulate pancreatic islet growth by promoting histone methylation and expression of cyclin-dependent kinase inhibitors p27 and p18 [18,19]. Moreover, the simultaneous loss of p18 and p27 in mice was shown to lead to development of tumors in many of the same endocrine tissues as humans with inherited mutations in the MEN1 and MEN2 genes [20]. These studies argue for a major role for p18 and p27 in the tissue-specific tumor phenotype in MEN1. Specifically, loss of menin prevents H3 K4 methylation at the promoters of p18 and p27, reducing their expression, and ultimately abrogating their inhibitory effect on cyclin-dependent kinases (CDK2 and CDK4) and resulting in unrestrained cell growth. Consistent with this hypothesis, we detected menin at the promoters of p18 and p27 and reduced p18 expression in islet cells that were conditionally null for Men1. However, p18 and p27 concentrations were reduced in Men1/ liver, which is not susceptible to developing tumors in heterozygous MEN1 patients, or in mice rendered null for menin in liver by a conditional knockout. A separate study showed that menin can regulate p18 and p27 expression in fibroblasts [19], yet the phenotype of MEN1 does not include fibrosarcoma. These results indicate that while dysregulation of p18 and p27 may contribute to neoplastic transformation in MEN1, these genes alone cannot account for the specific bias for endocrine tumor formation in MEN1.

To identify other possible genetic causes for the tissue specificity of tumor formation, we identified a relatively small number of genes that were both bound by menin and altered in expression in menin-null islets. One of these genes was the developmentally programmed HLXB9, which codes for transcription factor HB9. Hb9 expression was significantly elevated in pancreatic islets in the absence of menin, suggesting that menin is a transcriptional repressor of HLXB9. It is also noteworthy that HLXB9 was bound by menin only in islets, and not in HeLa or HepG2 cells. These findings raise the possibility that the specific bias for endocrine tumor formation in MEN1 could result from changes in expression in distinct genes, including HLXB9, that are specifically targeted by menin in endocrine tissues.

Based on our findings and the work of others, we propose the following model for tumor suppression by menin in pancreatic islets (Figure 8). In both endocrine and nonendocrine tissues, menin mediates transcriptional activation of genes that inhibit cell growth, including, but not limited to, the cyclin-dependent kinase inhibitors p18 and p27. In addition, menin can function as a corepressor of tissue-specific genes that promote cell growth, including HLXB9. Menin can mediate its regulatory functions in the presence of the HMT complexes or other menin partners. Endocrine neoplasia as a consequence of menin loss results from the combined effects of decreased p18 and p27 and increased HLXB9 expression. Additional tissue-specific factors that are dysregulated upon menin loss probably also contribute to neoplasia. Similar studies in additional tissues, such as anterior pituitary or parathyroid, may help reveal the complete list of critical targets.

Figure 8
Hypothetical Model of Menin Function

Materials and Methods

Antibodies for chromatin immunoprecipitation.

Affinity-purified rabbit polyclonal anti-menin (BL342), anti-Rbbp5 (BL766), and anti-MLL1 (BL1289) antibodies were obtained from Bethyl Laboratories (Montgomery, Texas, United States). The menin antibody recognizes an epitope at the C terminus of menin. The Rbbp5 antibody was raised against a portion of human Rbbp5 encoded within exons 13 and 14. The epitope recognized by anti-MLL1 maps to a region between residues 720 and 780 of MLL1. This epitope is found in the N-terminal 300-kDa fragment generated by proteolytic cleavage. Histone H3 K4 antibody (ab8580; Abcam, Cambridge, United Kingdom) reacts to trimethylated H3 K4 and shows weak reactivity to dimethylated H3 K4.

Microarrays used for ChIP-chip.

Two different DNA tiling microarray designs were used in this study. Both microarrays were printed by NimbleGen (Madison, Wisconsin, United States). The first array contained 190,181 oligonucleotides (70 nucleotides in length) representing HOX clusters A, B, C, and D, and approximately 230 loci tiled at an average resolution of one oligo every 150 to 350 bp. Roughly half of these 230 loci harbored genes whose protein products contain homeodomains. The remaining half were identified as positive “hits” in a pilot study using a previously described conventional microarray that contained portions of promoter regions of 13,000 human genes (unpublished data). For each of these 230 genes, oligonucleotides spanning −10 kb relative to the transcriptional start site to +10 kb relative to the end of the transcript were tiled. The coordinates for DNA corresponding to the HOX clusters based on the July 2003 human genome assembly are as follows: HOX A: Chromosome 7: 16,875,358 to 36,981,974; HOX B: Chromosome 17: 47,064,003 to 47,300,285; HOX C: Chromosome 12: 52,599,536 to 52,755,746; HOX D: Chromosome 2: 177,140,087 to 177,277,119. The second tiling microarray we designed contained oligonucleotides tiled across 19,928 promoter regions. The oligonucleotides were distributed at a resolution of approximately one 50 mer every 100 bp (1.5 kb approximately each promoter region). This array also contained tiling oligonucleotides across 381 genes (−5 kb relative to each transcriptional start site to +5 kb relative to the end of each transcript) at an average resolution of one oligo every 180 bp. The array also harbored tiling oligonucleotides across all four HOX clusters. The coordinates for DNA corresponding to the HOX clusters were based on the May 2004 human genome assembly and are as follows: HOX A: Chromosome 7: 26,901,743 to 27,173,542; HOX B: Chromosome 17: 43,958,347 to 44,167,626; HOX C: Chromosome 12: 52,616,715 to 52,738,384; HOX D: Chromosome 2: 176,780,780 to 176,883,479.

ChIP-chip.

The protocol described here was adapted from previously published studies [21,38]. Briefly, for each ChIP-chip experiment, 1 to 2 × 108 cells were crosslinked with 1% formaldehyde for 20 min at room temperature, harvested, and rinsed with 1× PBS. Cell nuclei were isolated, pelleted, and sonicated. DNA fragments were enriched by immunoprecipitation with factor-specific antibodies. After heat-reversal of the crosslinking, the enriched DNA was amplified by ligation-mediated PCR (LM-PCR) and then fluorescently labeled by using Klenow polymerase and Cy5-labeled dUTP (Amersham Biosciences, Piscataway, New Jersey, United States). A sample of DNA that was not enriched by immunoprecipitation was subjected to LM-PCR and labeled with Cy3-dUTP. ChIP-enriched and unenriched (input) labeled samples were cohybridized to microarrays. Microarrays were hybridized 18 to 20 h at 45 °C, washed according to the protocol described by NimbleGen, and scanned using an Agilent Technologies (Palo Alto, California, United States) microarray scanner. As a pilot study, the first custom-designed “HOX” array was hybridized with menin chromatin immunoprecipitated DNA from HeLa S3 cells from a single experiment. For experiments using the second, more promoter-oriented array design, three biological replicates were performed for experiments in HeLa S3 and HepG2 cells. In purified pancreatic islet preps, menin ChIP-chip was performed in biological quadruplicate, and Rbbp5 and H3 K4 experiments in duplicate. Due to limited availability of primary islet tissue, ChIP-chip in islet cells using antibodies to MLL1 was done once. Islet preparations were treated with formaldehyde in culture media between 1 h and 5 d after isolation from pancreata, which were derived from brain-dead organ donors (National Institutes of Health, Institutional Review Board exemption issued by National Institutes of Health Office of Human Subjects [IRB Exemption No. 3072]). For each ChIP-chip experiment, approximately 30,000 viable islet equivalents were fixed and handled as described above. Islet purity ranged from 40% to 90% with 60% to 90% viability.

Analysis of ChIP tiling array data.

Raw array data were normalized using bi-weight mean using the NimbleScan Version 2.1 software (NimbleGen Systems). Log2 ratios (cy5/cy3) from biological replicates were averaged. To identify potential sites of enrichment, a window and threshold strategy was used (Figure 1). Briefly, a 1,000-bp window was moved stepwise along the tiled region, centering at every probe. Hybridization signals of probes within each window were tested by χ2 analysis to determine if the window contained a higher than expected number of probes. These calculations resulted in a single p-value associated with each averaged data point. Analyses performed at different window sizes and thresholds yielded similar results (unpublished data). All raw and processed ChIP-chip data is publicly available from Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo). The p-value scores for each promoter tested are included. The windowing and threshold program we developed, which we named ACME (Algorithm for Capturing Microarray Enrichment), is available from the authors upon request.

Real-time PCR validation.

Standard ChIP with menin and trimethyl H3 K4 antibodies was performed on HeLa S3 cells in duplicate. PCR primer pairs were designed to amplify 150- to 200-bp fragments from selected genomic regions. For menin, we compared 67 promoters determined by ChIP-chip to be enriched for menin binding at p < 0.0001 to 15 random promoter regions (0.001 < p < 1) and seven random regions located outside of promoter regions. For H3 K4, we tested 38 promoters that were determined by ChIP-chip to be highly enriched (p < 0.0001), 20 marginally enriched genes (0.0001 < p < 0.001), 17 unenriched promoter regions (p > 0.5), and seven random regions.

Real-time PCRs were carried out in duplicate on each chromatin immunoprecipitated and input DNA sample using SYBR green PCR mix (Qiagen, Valencia, California, United States) in an Applied Biosystems 7900HT Fast Real Time-PCR machine (Foster City, California, United States). DNA obtained from menin chromatin immunoprecipitations was very limited in quantity and could not be quantitated by standard methods. As a result, unequal quantities of ChIP and input DNA were added to PCRs. To account for the differences in DNA quantity, for every genomic region studied, a ΔCt value was calculated for each sample by subtracting the Ct value for chromatin immunoprecipitated sample from the Ct value obtained for the input. Raising 2 to the ΔCt power yielded the relative amount of PCR product (relative enrichment). Average values for promoters occupied by either menin or H3 K4 were compared to those calculated for unoccupied promoters and random regions of the genome. All primer sequences are available upon request.

Comparison of ChIP-chip and expression data.

ChIP-chip data from islet cells were merged to Affymetrix (Santa Clara, California, United States) islet expression data from the Novartis (version 2) data set [39]. HeLa S3 and HepG2 ChIP-chip data were merged to expression data generated in our laboratory using Affymetrix U133A Plus microarrays (HeLa S3 and HepG2). All ChIP-chip and expression datasets were merged by gene symbol. For all three cell types, two replicate datasets were averaged. Average raw intensity values were converted to log base 2 and normalized using the robust multiarray average method (RMA) [40]. Data for genes represented by multiple probes were retained in the dataset. This analysis gave 10,148 genes in islet cells and 10,078 genes in HeLa S3 and HepG2 cells for which we had both binding and expression data.

Microarray analyses were also performed using RNA from highly pure islets prepared from 15-wk-old (n = 5) and 25-wk-old (n = 3) female mice that were conditionally null for Men1 (genotype: RIP-cre, Men1loxP/loxP). Controls included islet RNA prepared from sex-matched wild-type (n = 3) and RIP-cre (n = 2) mice at 15 wk of age. Total RNA isolated from each group of mice was pooled and subjected to two rounds of amplification three times. Biotin-labeled cRNA was then purified, fragmented, and hybridized to MOE430A Affymetrix GeneChip probe arrays containing more than 22,000 probe sets. Two-tailed t-tests using Microsoft Excel were used to compare expression values from wild-type and RIP-cre controls to 15-wk conditionally null mice (RIP-cre, Men1loxP/loxP). The mouse expression data were merged to the human ChIP-chip data, yielding 5,519 unique genes for which we had both expression and binding data.

Immunohistochemistry.

The pancreas from an 18-mo heterozygous Men1 knockout mouse (Men1+/) was removed, immediately fixed in 4% paraformaldehyde, and embedded in paraffin. Immunohistochemistry of pancreatic sections from an 18-mo conventional Men1 knockout mouse (Men1+/) was performed following antigen retrieval using previously described antibodies to Hb9 [25].

Supporting Information

Figure S1

The 184 Genes That Were Found to Separate 15-wk Men1-Null Islets from Controls Are Depicted in the Red-Green Color-Coded Plot (p < 0.01)

Relative expression levels have been pseudo-colored red and green, with red corresponding to high expression and green corresponding to low expression. The color-coded plot to the right of the expression data represents ChIP-chip p-value binding data for each factor. Color key: red, p < 0.0001; orange, 0.0001 > p < 0.001; gold, 0.001 > p < 0.01; light yellow, 0.01 > p <0.1; white, p > 0.1. Twenty-four genes whose promoters were bound by menin exclusively in islets are depicted in red and blue. Those in red show statistically significant differences in expression at both the 15- and 25-wk time points (p < 0.01).

(142 KB PDF)

Acknowledgments

We give special thanks to Richard Young, Mike Erdos, Darryl Leja, and Yuan Jiang for assistance and helpful discussions. We also thank NimbleGen Systems, Inc. for assistance with tiled microarray design, especially Roland Green and Mike Singer. Primary human pancreatic islet isolates were provided by the Islet Cell Resource Centers.

Abbreviations

ChIP-chip
chromatin-immunoprecipitation coupled with microarray analysis
MEN1
multiple endocrine neoplasia, type I

Footnotes

Author contributions. PCS conceived and designed the experiments. PCS, SP, and MJH performed the experiments. PCS, SD, SKA, and FSC analyzed the data. PCS, DTO, GEC, SKA, PSM, and FSC contributed reagents/materials/analysis tools. SJM and AMS advised and contributed intellectually. PCS wrote the paper.

Funding. This research was supported by grants from the National Institutes of Health (DTO: NIDDK K25-DK070813; NIDDK R01-DK068655) and the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health.

Competing interests. The authors have declared that no competing interests exist.

A previous version of this article appeared as an Early Online Release on February 23, 2006 (DOI: 10.1371/journal.pgen.0020051.eor).

Citation: Scacheri PC, Davis S, Odom DT, Crawford GE, Perkins S, et al. (2006) Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet 2(4): e51. DOI: 10.1371/journal.pgen.0020051

References

  • Knudson AG., Jr. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68:820–823. [PMC free article] [PubMed]
  • Debelenko LV, Brambilla E, Agarwal SK, Swalwell JI, Kester MB, et al. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet. 1997;6:2285–2290. [PubMed]
  • Farnebo F, Teh BT, Kytola S, Svensson A, Phelan C, et al. Alterations of the MEN1 gene in sporadic parathyroid tumors. J Clin Endocrinol Metab. 1998;83:2627–2630. [PubMed]
  • Heppner C, Kester MB, Agarwal SK, Debelenko LV, Emmert-Buck MR, et al. Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet. 1997;16:375–378. [PubMed]
  • Zhuang Z, Ezzat SZ, Vortmeyer AO, Weil R, Oldfield EH, et al. Mutations of the MEN1 tumor suppressor gene in pituitary tumors. Cancer Res. 1997;57:5446–5451. [PubMed]
  • Zhuang Z, Vortmeyer AO, Pack S, Huang S, Pham TA, et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res. 1997;57:4682–4686. [PubMed]
  • Guru SC, Goldsmith PK, Burns AL, Marx SJ, Spiegel AM, et al. Menin, the product of the MEN1 gene, is a nuclear protein. Proc Natl Acad Sci U S A. 1998;95:1630–1634. [PMC free article] [PubMed]
  • Bertolino P, Tong WM, Galendo D, Wang ZQ, Zhang CX. Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Mol Endocrinol. 2003;17:1880–1892. [PubMed]
  • Crabtree JS, Scacheri PC, Ward JM, Garrett-Beal L, Emmert-Buck MR, et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci U S A. 2001;98:1118–1123. [PMC free article] [PubMed]
  • Bertolino P, Tong WM, Herrera PL, Casse H, Zhang CX, et al. Pancreatic beta-cell-specific ablation of the multiple endocrine neoplasia type 1 (MEN1) gene causes full penetrance of insulinoma development in mice. Cancer Res. 2003;63:4836–4841. [PubMed]
  • Biondi CA, Gartside MG, Waring P, Loffler KA, Stark MS, et al. Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues. Mol Cell Biol. 2004;24:3125–3131. [PMC free article] [PubMed]
  • Crabtree JS, Scacheri PC, Ward JM, McNally SR, Swain GP, et al. Of mice and MEN1: Insulinomas in a conditional mouse knockout. Mol Cell Biol. 2003;23:6075–6085. [PMC free article] [PubMed]
  • Scacheri PC, Kennedy AL, Chin K, Miller MT, Hodgson JG, et al. Pancreatic insulinomas in multiple endocrine neoplasia, type I knockout mice can develop in the absence of chromosome instability or microsatellite instability. Cancer Res. 2004;64:7039–7044. [PubMed]
  • Scacheri PC, Crabtree JS, Kennedy AL, Swain GP, Ward JM, et al. Homozygous loss of menin is well tolerated in liver, a tissue not affected in MEN1. Mamm Genome. 2004;15:872–877. [PubMed]
  • Agarwal SK, Kennedy PA, Scacheri PC, Novotny EA, Hickman AB, et al. Menin molecular interactions: Insights into normal functions and tumorigenesis. Horm Metab Res. 2005;37:369–374. [PubMed]
  • Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland TD, Levine SS, et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell. 2004;13:587–597. [PubMed]
  • Yokoyama A, Wang Z, Wysocka J, Sanyal M, Aufiero DJ, et al. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate hox gene expression. Mol Cell Biol. 2004;24:5639–5649. [PMC free article] [PubMed]
  • Karnik SK, Hughes CM, Gu X, Rozenblatt-Rosen O, McLean GW, et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci U S A. 2005;102:14659–14664. [PMC free article] [PubMed]
  • Milne TA, Hughes CM, Lloyd R, Yang Z, Rozenblatt-Rosen O, et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A. 2005;102:749–754. [PMC free article] [PubMed]
  • Franklin DS, Godfrey VL, O'Brien DA, Deng C, Xiong Y. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol. 2000;20:6147–6158. [PMC free article] [PubMed]
  • Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, et al. Control of pancreas and liver gene expression by HNF transcription factors. Science. 2004;303:1378–1381. [PMC free article] [PubMed]
  • Bernstein BE, Kamal M, Lindblad-Toh K, Bekiranov S, Bailey DK, et al. Genomic maps and comparative analysis of histone modifications in human and mouse. Cell. 2005;120:169–181. [PubMed]
  • Arber S, Han B, Mendelsohn M, Smith M, Jessell TM, et al. Requirement for the homeobox gene Hb9 in the consolidation of motor neuron identity. Neuron. 1999;23:659–674. [PubMed]
  • Habener JF, Kemp DM, Thomas MK. Minireview: Transcriptional regulation in pancreatic development. Endocrinology. 2005;146:1025–1034. [PubMed]
  • Harrison KA, Thaler J, Pfaff SL, Gu H, Kehrl JH. Pancreas dorsal lobe agenesis and abnormal islets of Langerhans in Hlxb9-deficient mice. Nat Genet. 1999;23:71–75. [PubMed]
  • Li H, Arber S, Jessell TM, Edlund H. Selective agenesis of the dorsal pancreas in mice lacking homeobox gene Hlxb9. Nat Genet. 1999;23:67–70. [PubMed]
  • Li H, Edlund H. Persistent expression of Hlxb9 in the pancreatic epithelium impairs pancreatic development. Dev Biol. 2001;240:247–253. [PubMed]
  • Belloni E, Martucciello G, Verderio D, Ponti E, Seri M, et al. Involvement of the HLXB9 homeobox gene in Currarino syndrome. Am J Hum Genet. 2000;66:312–319. [PMC free article] [PubMed]
  • Hagan DM, Ross AJ, Strachan T, Lynch SA, Ruiz-Perez V, et al. Mutation analysis and embryonic expression of the HLXB9 Currarino syndrome gene. Am J Hum Genet. 2000;66:1504–1515. [erratum appears in Am J Hum Genet (2000) 67: 769]. [PMC free article] [PubMed]
  • Lynch SA, Wang Y, Strachan T, Burn J, Lindsay S. Autosomal dominant sacral agenesis: Currarino syndrome. J Med Genet. 2000;37:561–566. [PMC free article] [PubMed]
  • Beverloo HB, Panagopoulos I, Isaksson M, van Wering E, van Drunen E, et al. Fusion of the homeobox gene HLXB9 and the ETV6 gene in infant acute myeloid leukemias with the t(7;12)(q36;p13) Cancer Res. 2001;61:5374–5377. [PubMed]
  • Nagel S, Kaufmann M, Scherr M, Drexler HG, MacLeod RA. Activation of HLXB9 by juxtaposition with MYB via formation of t(6;7)(q23;q36) in an AML-M4 cell line (GDM-1) Genes Chromosomes Cancer. 2005;42:170–178. [PubMed]
  • Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30:41–47. [PubMed]
  • Ayton PM, Cleary ML. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 2003;17:2298–2307. [PMC free article] [PubMed]
  • Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1:75–87. [PubMed]
  • Kumar AR, Hudson WA, Chen W, Nishiuchi R, Yao Q, et al. Hoxa9 influences the phenotype but not the incidence of Mll-AF9 fusion gene leukemia. Blood. 2004;103:1823–1828. [PubMed]
  • Zeisig BB, Milne T, Garcia-Cuellar MP, Schreiner S, Martin ME, et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol. 2004;24:617–628. [PMC free article] [PubMed]
  • Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, et al. E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints. Genes Dev. 2002;16:245–256. [PMC free article] [PubMed]
  • Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A. 2004;101:6062–6067. [PMC free article] [PubMed]
  • Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31:e15. [PMC free article] [PubMed]

Articles from PLoS Genetics are provided here courtesy of Public Library of Science
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...